<DOC>
	<DOCNO>NCT03037944</DOCNO>
	<brief_summary>This study aim compare efficacy LNG - IUD ( Levonorgestrel release intrauterine device ) Versus Low dose COCs ( combine oral contraceptive pill ) management heavy menstrual bleeding Dysmenorrhea cause Adenomyosis .</brief_summary>
	<brief_title>Levonorgestrel-releasing Intrauterine System Versus Low-dose Combined Oral Contraceptive Management Adenomyosis Uteri</brief_title>
	<detailed_description>Levonorgestrel release intrauterine device MetraPlant-E , use study group A , modify Levonorgestrel -releasing intrauterine system old IUD - Intrauterine Device `` Metraplant '' , MetraPlant-E design T-shaped frame contain Levonorgestrel Ethylene Vinyl Acetate well Barium Sulphate make radio-opaque , All `` T '' frame , bulb 20 mm length sleeves contain : Ethylene Vinyl Acetate , Levonorgestrel Barium Sulphate , ensure exposure endometrial surface system hence expect endometrial suppression . It consist Levonorgestrel Hormone ( 60 mg ) , Ethylene Vinyl Acetate ( 120 mg ) &amp; Barium Sulphate ( 20 mg ) Metraplant-E design without coat membrane , help rise Levonorgestrel level ( high initial release ) . The high initial release Levonorgestrel ( reach 28Âµg/24hrs Metraplant-E study in-vitro release ) may help early stoppage bleeding patient suffer irregular bleeding . Women group A receive IUD - Intrauterine Device- menstruation .It insert uterus similar procedure non-hormonal IUD .Pelvic exam do , vagina hold open speculum , grasp cervix , measure uterine length proper insertion IUD - Intrauterine Device non-touch technic . Women receive proper antibiotic insertion . Group B receive combine oral contraceptive pill ( Yasmin ) Monophasic pills constant dose estrogen progestin hormonal active pill throughout entire cycle . Yasmin ( ethinyl estradiol 0.03 mg/ drospirenone 3 mg ) tablet , provide oral contraceptive regimen , use continuously 6 month stoppage 3 month withdrawal bleeding . Both treatment arm ( Metraplant E Yasmin ) follow 3 month 6 month patient ' recruitment . Assessment pain relate symptom do use visual analogue scale pain score , assessment menstrual improvement do use menstrual diary .</detailed_description>
	<mesh_term>Adenomyosis</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Women patient age 3045 year Diagnosed adenomyosis transvaginal ultrasound MRI 3D ultrasound Patient complain heavy menstrual bleeding dysmenorrhea Living nearby area make followup reasonably possible Planning birth space least 2 year . Pregnancy seek fertility Severe underlie comorbidities ( hepatic , oncological ) Pelvic inflammatory disease Other cervical uterine pathology Deep venous thromboembolism Hormonal therapy contraindication Endometriosis fibroid</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adenomyosis</keyword>
	<keyword>Contraceptive pill</keyword>
	<keyword>Levonorgestrel-releasing Intrauterine System</keyword>
</DOC>